BioCryst Pharmaceuticals (BCRX)
(Delayed Data from NSDQ)
$7.52 USD
-0.33 (-4.20%)
Updated Jul 29, 2024 04:00 PM ET
After-Market: $7.51 -0.01 (-0.13%) 7:58 PM ET
1-Strong Buy of 5 1
F Value C Growth F Momentum F VGM
Brokerage Reports
0 items in cart
BioCryst Pharmaceuticals, Inc. [BCRX]
Reports for Purchase
Showing records 121 - 140 ( 176 total )
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Phase 2b Gout Trial Meets Primary Endpoint - Lowest Dose Surprisingly Effective
Provider: RODMAN & RENSHAW, CO.
Analyst: NOCHOMOVITZ Y
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Phase 2b Gout Trial Meets Primary Endpoint - Lowest Dose Surprisingly Effective
Provider: RODMAN & RENSHAW, CO.
Analyst: NOCHOMOVITZ Y
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Presentations at ICAAC Highlight Peramivir - Gout Remains Key Driver
Provider: RODMAN & RENSHAW, CO.
Analyst: NOCHOMOVITZ Y
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Presentations at ICAAC Highlight Peramivir ? Gout Remains Key Driver
Provider: RODMAN & RENSHAW, CO.
Analyst: NOCHOMOVITZ Y
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Updates from Meeting with BioCryst Management at Rodman & Renshaw Conference
Provider: RODMAN & RENSHAW, CO.
Analyst: NOCHOMOVITZ Y
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Updates from Meeting with BioCryst Management at Rodman & Renshaw Conference
Provider: RODMAN & RENSHAW, CO.
Analyst: NOCHOMOVITZ Y
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Transformative Data Coming Up & Trading at Just $80 MM EV -Reiterating Outperform
Provider: RODMAN & RENSHAW, CO.
Analyst: NOCHOMOVITZ Y
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Transformative Data Coming Up & Trading at Just $80 MM EV - Reiterating Outperform
Provider: RODMAN & RENSHAW, CO.
Analyst: NOCHOMOVITZ Y
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Key Takeaways on the Gout Landscape from Our Conversation with Dr. Robert Terkeltaub
Provider: RODMAN & RENSHAW, CO.
Analyst: NOCHOMOVITZ Y
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Key Takeaways on the Gout Landscape from Our Conversation with Dr. Robert Terkeltaub
Provider: RODMAN & RENSHAW, CO.
Analyst: NOCHOMOVITZ Y
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Peramivir Appears to Retain Activity Against a Novel Strain of A(H1N1) Influenza
Provider: RODMAN & RENSHAW, CO.
Analyst: NOCHOMOVITZ Y
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Peramivir Appears to Retain Activity Against a Novel Strain of A(H1N1) Influenza
Provider: RODMAN & RENSHAW, CO.
Analyst: NOCHOMOVITZ Y
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Additional Studies Planned to Strengthen Gout Drug Safety Profile Presented at EULAR
Provider: RODMAN & RENSHAW, CO.
Analyst: NOCHOMOVITZ Y
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Additional Studies Planned to Strengthen Gout Drug Safety Profile Presented at EULAR
Provider: RODMAN & RENSHAW, CO.
Analyst: NOCHOMOVITZ Y